Mauro Magnani
Mauro Magnani
Professor of Biochemsitry
Email verificata su
Citata da
Citata da
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells
V Stocchi, L Cucchiarini, M Magnani, L Chiarantini, P Palma, ...
Analytical biochemistry 146 (1), 118-124, 1985
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
Development of a real-time PCR assay for rapid detection and quantification of Alexandrium minutum (a dinoflagellate)
L Galluzzi, A Penna, E Bertozzini, M Vila, E Garcs, M Magnani
Applied and environmental microbiology 70 (2), 1199-1206, 2004
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
Oncologist 13 (12), 1270, 2008
Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals
M Paiardini, B Cervasi, H Albrecht, A Muthukumar, R Dunham, S Gordon, ...
The Journal of Immunology 174 (5), 2900-2909, 2005
Cell-based drug delivery
F Pierig, S Serafini, L Rossi, M Magnani
Advanced drug delivery reviews 60 (2), 286-295, 2008
The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB)
M Magnani, R Crinelli, M Bianchi, A Antonelli
Current drug targets 1 (4), 387-399, 2000
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ...
European journal of cancer 44 (13), 1875-1882, 2008
A new platform for Real-Time PCR detection of Salmonella spp., Listeria monocytogenes and Escherichia coli O157 in milk
E Omiccioli, G Amagliani, G Brandi, M Magnani
Food microbiology 26 (6), 615-622, 2009
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ...
J Clin Oncol 24 (12), 1883-1891, 2006
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer
F Graziano, N Galluccio, P Lorenzini, A Ruzzo, E Canestrari, S D'Emidio, ...
J Clin Oncol 29 (36), 4789-4795, 2011
Design and characterization of decoy oligonucleotides containing locked nucleic acids
R Crinelli, M Bianchi, L Gentilini, M Magnani
Nucleic acids research 30 (11), 2435-2443, 2002
Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART
G Marchetti, A Gori, A Casabianca, M Magnani, F Franzetti, M Clerici, ...
Aids 20 (13), 1727-1736, 2006
Erythrocyte-based drug delivery
L Rossi, S Serafini, F Pierig, A Antonelli, A Cerasi, A Fraternale, ...
Expert opinion on drug delivery 2 (2), 311-322, 2005
Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of…
JM Lhr, R Faissner, D Koczan, P Bewerunge, C Bassi, B Brors, R Eils, ...
The American journal of gastroenterology 105 (9), 2060, 2010
Erythrocyte engineering for drug delivery and targeting
M Magnani, L Rossi, M D'ascenzo, I Panzani, L Bigi, A Zanella
Biotechnology and applied biochemistry 28 (1), 1-6, 1998
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
F Graziano, A Ruzzo, F Loupakis, E Canestrari, D Santini, V Catalano, ...
Journal of Clinical Oncology 26 (9), 1427-1434, 2008
Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer
F Graziano, F Arduini, A Ruzzo, I Bearzi, B Humar, H More, R Silva, ...
Clinical Cancer Research 10 (8), 2784-2789, 2004
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–20